Q-omics provides the consensus-scored DEFB108B profile across patient tissues and cancer cell-line models. DEFB108B expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, DEFB108B is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, DEFB108B RNA expression shows 11,247 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight THCA, KIRC, and TGCT as cancer lineages where DEFB108B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEFB108B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEFB108B survival associations across molecular data types. DEFB108B RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEFB108B RNA expression–survival associations across cancer types. High DEFB108B expression shows unfavorable associations in THCA, READ, SKCM, BLCA, COAD and UVM. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify THCA as the clearest survival context for DEFB108B RNA expression.
This table summarizes DEFB108B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DEFB108B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEFB108B shows lower tumor expression in THCA and higher tumor expression in KIRC and LUSC. The KIRC box plot shows higher DEFB108B RNA expression in tumor versus normal tissue (log2 FC = +0.045, t-test p = .013).
This table shows molecular features associated with DEFB108B in patient tissues and cancer cell lines. In patient samples, DEFB108B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, DEFB108B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
